Description
Release form
Tablets.
Packing
10 pcs.
Pharmacological action
Artrozan ® is a non-steroidal anti-inflammatory drug (NSAID) that has anti-inflammatory, antipyretic and analgesic effects.
Belongs to the class of oxycams, is a derivative of enolic acid.
The mechanism of action is associated with the inhibition of prostaglandin synthesis as a result of selective inhibition of the enzymatic activity of type 2 cyclooxygenase (COX-2), which is involved in prostaglandin biosynthesis in the area of inflammation. When prescribed in high doses, prolonged use and individual characteristics of the body, selectivity for COX-2 is reduced. To a lesser extent, it affects the first type cyclooxygenase (COX-1), which is involved in the synthesis of prostaglandins that protect the gastrointestinal mucosa and take part in the regulation of blood flow in the kidneys. Due to the indicated selectivity of suppressing the activity of COX-2, the drug less often causes erosive and ulcerative lesions of the gastrointestinal tract.
Indications
Symptomatic treatment of inflammatory and degenerative diseases of the muscular-joint system associated with pain, including:
Osteoarthritis.
Rheumatoid Arthritis.
Ankylosing spondylitis (ankylosing spondylitis).
Osteochondrosis.
Contraindications
Hypersensitivity to meloxicam or auxiliary components of the drug.
The composition includes lactose, so patients with rare hereditary diseases, such as galactose intolerance, lactase deficiency or glucose-galactose malabsorption, should not take the drug.
Decompensated heart failure.
Early postoperative period after coronary artery bypass grafting.
Complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance to acetylsalicylic acid or other NSAIDs (including a history).
Exacerbation of peptic ulcer of the stomach and duodenum active gastrointestinal bleeding.
Inflammatory bowel disease (ulcerative colitis, Crohn’s disease in the acute stage).
Cerebrovascular bleeding or other bleeding.
Severe liver failure or active liver disease.
Chronic renal failure (in patients not undergoing hemodialysis (CC less than 30 ml / min).
Progressive kidney disease, including confirmed hyperkalemia.
Children under 15 years of age.
Pregnancy.
Breastfeeding period
caution: the drug should be used with caution in elderly patients and in the presence of the following medical conditions: coronary heart disease, congestive heart failure, cerebrovascular disease, dyslipidemia / hyperlipidemia, diabetes mellitus, peripheral disease blood vessels, chronic renal failure with creatinine clearance of 30-60 ml / min, ulcerative lesions of the gastrointestinal tract, the presence of Helicobacter pylori infection, prolonged use of NSAIDs, alcohol abuse, concomitant therapy with anticoagulants (e.g. warfarin), antiplatelet agents (e.g. acetylsalicylic acid, clopidogrel), oral glucocorticosteroids (e.g. prednisone), selective serotonin reuptake inhibitors (e.g. citalopram, fluoxetine, sertraline, paroxetine) must be taken into account when prescribing meloxicam.
To reduce the risk of adverse events from the gastrointestinal tract, the minimum effective dose should be used with the shortest possible course.
Use during pregnancy and lactation
Contraindicated in pregnancy and lactation.
Special instructions
Caution should be exercised when using the drug in patients with a history of gastric and duodenal ulcer and patients on anticoagulant therapy. Such patients have an increased risk of erosive and ulcerative diseases of the gastrointestinal tract.
Caution should be exercised and daily diuresis and renal function should be monitored when using the drug in the elderly and patients with reduced BCC and decreased glomerular filtration (dehydration, chronic heart failure, cirrhosis, nephrotic syndrome, clinically pronounced kidney disease, diuretics, dehydration after major surgeries).
In patients with a slight or moderate decrease in renal function (creatinine clearance 30-60 ml / min) dose adjustment is not required.
Patients taking both diuretics and meloxicam should take enough fluids.
In case of allergic reactions (itching, skin rash, urticaria, photosensitivity) during treatment, you should consult a doctor to resolve the issue of stopping the drug.
Meloxicam, like other NSAIDs, can mask the symptoms of infectious diseases.
The use of meloxicam, as well as other drugs that block the synthesis of prostaglandins, can affect fertility, therefore it is not recommended for use in women, planning a pregnancy.
Influence on the ability to drive vehicles and control mechanisms
The use of the drug can cause headaches, dizziness and drowsiness. If these phenomena occur, you should refuse to drive vehicles and perform other potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.
Composition of
1 tablet contains:
active substance: meloxicam – 15 mg
excipients: potato starch 94 monolidone lactone polylhydrolone lapolide 150 mg mg molecular weight medical) 4.5 mg, sodium citrate 27 mg, magnesium stearate 3 mg, colloidal silicon dioxide (aerosil) 6 mg.
Dosage and administration of
The drug is taken orally during meals at a daily dose of 7.5-15 mg.
Recommended dosage:
Rheumatoid arthritis: 15 mg per day. If necessary, the dose can be reduced to 7.5 mg per day.
Osteoarthrosis, osteochondrosis and other inflammatory and degenerative diseases of the muscular-joint system, accompanied by pain: 7.5 mg per day. With inefficiency, the dose can be increased to 15 mg per day.
Ankylosing spondylitis: 15 mg per day. The maximum daily dose should not exceed 15 mg.
In patients with an increased risk of side effects, as well as in patients with severe renal failure undergoing hemodialysis: the dose should not exceed 7.5 mg per day.
Side effects of
From the digestive system: more than 1% – dyspepsia, including nausea, vomiting, abdominal pain, diarrhea, constipation, flatulence 0.1-1% – a transient increase in the activity of liver transaminases, hyperbilirubinemia, belching, esophagitis, gastric or duodenal ulcer, gastrointestinal bleeding (hidden or obvious), stomatitis less than 0.1% – perforation of the digestive tract, colitis, hepatitis, gastritis.
From the hemopoietic organs: more than 1% – anemia 0.1-1% – leukopenia, thrombocytopenia.
From the skin: more than 1% – itching, skin rash 0.1-1% – urticaria less than 0.1% – photosensitivity, bullous rashes, erythema multiforme, incl. Stevens-Johnson syndrome, toxic epidermal necrolysis.
From the respiratory system: less than 0.1% – bronchospasm.
From the side of the central nervous system: more than 1% – dizziness, headache 0.1-1% – tinnitus, drowsiness less than 0.1% – emotional lability, confusion, disorientation.
From the CCC side: more than 1% – peripheral edema 0.1-1% – increased blood pressure, palpitations, hyperemia of the face.
From the urinary system: 0.1-1% – hypercreatininemia, increased serum urea concentration of less than 0.1% – acute renal failure, no connection with meloxicam intake – interstitial nephritis, albuminuria, hematuria.
From the sensory organs: less than 0.1% – conjunctivitis, blurred vision.
Allergic reactions: less than 0.1% – angioedema, anaphylactic, anaphylactoid reactions.
Drug Interactions
When used simultaneously with other non-steroidal anti-inflammatory drugs (including acetylsalicylic acid), the risk of erosive and ulcerative lesions and bleeding of the gastrointestinal tract increases.
With simultaneous use with antihypertensive drugs, the effectiveness of the latter may decrease.
With simultaneous use with lithium preparations, it is possible to develop cumulation of lithium and increase its toxic effect (it is recommended to control the concentration of lithium in the blood).
With simultaneous use with methotrexate, the side effect of the latter on the hematopoietic system is increased (the risk of anemia and leukopenia, periodic monitoring of a general blood test is indicated).
When used simultaneously with diuretics and cyclosporine, the risk of developing renal failure increases.
With simultaneous use with intrauterine contraceptives, the effectiveness of the latter may be reduced.
When used simultaneously with anticoagulants (heparin, warfarin), thrombolytic drugs (streptokinase, fibrinolysin), and antiplatelet agents (ticlopidine, clopidogrel, acetysalicylic acid), the risk of bleeding increases (periodic monitoring of blood coagulability is necessary).
With simultaneous use with colestyramine, the excretion of meloxicam through the gastrointestinal tract is accelerated.
Concomitant use with selective serotonin reuptake inhibitors increases the risk of gastrointestinal bleeding.
Overdose
Symptoms: impaired consciousness, nausea, vomiting, epigastric pain, gastrointestinal bleeding, acute renal failure, liver failure, respiratory arrest, asystole.
Treatment: there are no specific antidotes and antagonists. In case of overdose of the drug – gastric lavage, intake of activated charcoal (within the next hour), symptomatic therapy. Forced diuresis, alkalinization of urine, hemodialysis are ineffective due to the high association of the drug with blood proteins.
Storage conditions
Do not store above 25 ° C.
Keep out of the reach and sight of children.
active substance
Meloxicam
Prescription conditions from
pharmacies Prescription
lekarstvennaja form
tablets
Prescribing
Children over 14 years old, Adults p173f4frd prd33f17 pf33pfrd17 pf3317 pf3317 , For children prescribed by a doctor, For adults as prescribed by a doctor
Indications
Indications
Radiculitis, rheumatoid arthritis, osteochondrosis, periarthritis, sciatica, lumbago, Osteoarthritis
Pharmstandart-Leksredstva, Russia
